These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 19439721)

  • 21. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Sorensen PS; Bertolotto A
    Neurology; 2007 Oct; 69(15):1552; author reply 1553. PubMed ID: 17923618
    [No Abstract]   [Full Text] [Related]  

  • 22. Immunosuppression for multiple sclerosis.
    N Engl J Med; 1983 Jul; 309(4):239-41. PubMed ID: 6866042
    [No Abstract]   [Full Text] [Related]  

  • 23. Quinpramine: revival of old anti-inflammatory principles in multiple sclerosis?
    Haghikia A; Gold R
    Exp Neurol; 2009 Jun; 217(2):240-1. PubMed ID: 19361499
    [No Abstract]   [Full Text] [Related]  

  • 24. [Cyclophosphamide in the therapy of multiple sclerosis].
    Salvatores U; Majeron M; Mascetti A
    Riv Sper Freniatr Med Leg Alien Ment; 1972 Feb; 96(1):163-84. PubMed ID: 4337775
    [No Abstract]   [Full Text] [Related]  

  • 25. Early treatment of multiple sclerosis to prevent neurologic damage.
    Coyle PK
    Neurology; 2008 Dec; 71(24 Suppl 3):S3-7. PubMed ID: 19064872
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunosuppression armamentarium in 2010: mechanistic and clinical considerations.
    Urschel S; Altamirano-Diaz LA; West LJ
    Pediatr Clin North Am; 2010 Apr; 57(2):433-57, table of contents. PubMed ID: 20371046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclophosphamide therapy for MS.
    Gauthier SA; Weiner HL
    Int MS J; 2005 Aug; 12(2):52-8. PubMed ID: 16417815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reason for hope: the advent of disease-modifying therapies in multiple sclerosis.
    O'Connor PW
    CMAJ; 2000 Jan; 162(1):83-4. PubMed ID: 11216206
    [No Abstract]   [Full Text] [Related]  

  • 29. Therapeutic trials for multiple sclerosis.
    McKhann GM
    Ann Neurol; 1990 Jun; 27(6):589-90. PubMed ID: 2193612
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical trials of immunosuppression and immunomodulation in multiple sclerosis.
    Kappos L
    J Neuroimmunol; 1988 Dec; 20(2-3):261-8. PubMed ID: 3058744
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunopathogenesis of multiple sclerosis: implications for treatment.
    Waldron-Lynch F; Hennessy MJ
    Ir Med J; 2004 Jan; 97(1):5-6. PubMed ID: 15055909
    [No Abstract]   [Full Text] [Related]  

  • 32. Principles of a new treatment algorithm in multiple sclerosis.
    Hartung HP; Montalban X; Sorensen PS; Vermersch P; Olsson T
    Expert Rev Neurother; 2011 Mar; 11(3):351-62. PubMed ID: 21375441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Experiences with immunosuppressive treatment of multiple sclerosis].
    Wieczorek V; Lehnert W; Brodkorb W
    Dtsch Gesundheitsw; 1971 Sep; 26(38):1791-4. PubMed ID: 5142348
    [No Abstract]   [Full Text] [Related]  

  • 34. Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Polman CH; Deisenhammer F; Giovannoni G; Killestein J; Schellekens H
    Neurology; 2007 Oct; 69(15):1553-4; author reply 1555. PubMed ID: 17923619
    [No Abstract]   [Full Text] [Related]  

  • 35. Natalizumab: bound to rebound?
    Schiess N; Calabresi PA
    Neurology; 2009 Feb; 72(5):392-3. PubMed ID: 19188569
    [No Abstract]   [Full Text] [Related]  

  • 36. [Mitoxantrone for the treatment of patients with multiple sclerosis].
    Komori M; Kondo T; Tanaka M
    Brain Nerve; 2009 May; 61(5):575-80. PubMed ID: 19514518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multiple sclerosis in childhood: understanding and caring for children with an "adult" disease.
    Boyd JR; MacMillan LJ
    Axone; 2000 Dec; 22(2):15-21. PubMed ID: 11901486
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Link of the mechanisms of action of glatiramer acetate to its long-term clinical data.
    Moreau T
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S12-5. PubMed ID: 19200858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Late results of the treatment of the chronic progressive form of multiple sclerosis by intensive immunosuppression].
    Wender M; Tokarz-Kupczyk E; Mularek O
    Neurol Neurochir Pol; 1989; 23(3):188-92. PubMed ID: 2561379
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Aspects of immunosuppressive therapy of multiple sclerosis].
    Fischer W
    Psychiatr Neurol Med Psychol Beih; 1975; 20-21():23-6. PubMed ID: 829627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.